Dr Jorg Taubel, MD FFPM FESC
Chief Executive Officer and Founder

Dr Jorg Taubel is medical practitioner and CEO of Richmond Pharmacology, a centre of excellence for experimental medicine studies, which he co-founded in 2001. A specialist in clinical pharmacology, Dr Taubel has extensive experience in cardiology, neurology, gastroenterology, and ethnic bridging studies. He was Principal Investigator in over 500 clinical trials in Phases 1 – 3. He is an MHRA recognised investigator for First in Human trials involving healthy and/or patient participants.

Dr Taubel has dosed the first patient in a pioneering global FIH study of NTLA-2001, the first CRISPR-Cas9 in vivo gene editing for transthyretin (TTR) amyloidosis. Since then, he has dosed patients in other in vivo gene editing trials, making Richmond the largest centre in this field globally. Working in close collaboration with The National Amyloidosis Centre at Royal Free Hospital, Dr Taubel has enrolled the largest cohorts of ATTR heart failure patients in every one of five pivotal studies.

Dr Taubel also established the Richmond Research Institute, a not-for-profit organisation dedicated to academic research.

Educated in Frankfurt, Germany, Dr Jorg Taubel graduated in medicine at Goethe-Universität in 1987 and achieved a postgraduate M.D in cardio-psychology awarded by the same university. In 1999, Dr Taubel was awarded a Diploma in Pharmaceutical Medicine by the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians.

Dr Jorg Taubel is an honorary senior research fellow at the Molecular and Clinical Sciences Research Institute at St George's University of London.  He has a special interest in cardiac repolarisation changes related to iatrogenic interference with glucostasis.

Dr Taubel is a visiting professor at King’s College London overseeing research into AI Ecoanalysis tools.  

Dr Taubel first proposed to utilise the physiological ECG changes following a meal to establish assay sensitivity in thorough QT studies; this may be accepted by the FDA as an alternative to the pharmacological challenge with moxifloxacin (Taubel 2012). He has studied the effects of meals on cardiac repolarisation and the underlying autonomic and humoral effects on cardiac ion channels in healthy and patient populations (Taubel 2019).

Dr Taubel is a Fellow of the European Society of Cardiology (ESC), the Faculty of Pharmaceutical Medicine (FPM) of the Royal Colleges of Physicians of the United Kingdom, the Royal Society of Medicine and the Institute of Directors (IOD).

Dr Taubel has authored over 200 publications in peer reviewed journals and presented his research at international events in Europe, Japan and the USA. He is a peer reviewer for various journals including the British Journal of Clinical Pharmacology, Clinical Pharmacology in Drug Development and New England Journal of Medicine.

He is the President Elect in the Arbeitsgemeinschaft Angewandte Humanpharmakologie (AGAH).

‍